Vital3D, headquartered in Vilnius, Lithuania, is a biotechnology company. Their work has resulted in an important advance in veterinary medicine—the world’s first bioprinter wound patch for pets. With this groundbreaking new technology QTVOmni, pet owners can truly make a difference in the way their animals’ wounds get treated. In the meantime, the company’s sights are on creating transplantable human organs in the next 10 years.
Eli and the team’s bioprinting process uses a patented laser-based platform which enables them to precisely expel living cells and biomaterials. This technology mimics the complex tissue architectures seen in native tissue providing unprecedented opportunities for veterinary and human healthcare. Vital3D‘s CEO, Vidmantas Šakalys, founded the company after witnessing the loss of a mentor to urinary cancer. His long-term vision doesn’t just stop at 3D-printing organs like kidneys, though—he’s working on new ways to treat cancer.
The Wound Patch Initiative
Vital3D cares about what pet owners want. Retivators They provide a cutting-edge wound patch for the price of €300, or €150 on wholesale. This is another revolutionary product that promises to significantly reduce costs of treatment for pet owners. They might not save more than €3,000 let alone saving €1,500! With this breakthrough, the company is confident that it can dramatically improve the recovery outcome of pets with complex wounds.
Pre-clinical testing of the bioprinted patches is scheduled to start this summer in both Lithuania and the UK. To start, we’ll narrow in on wound healing in canines. While it has been a proof of concept, we hope that this project can lead to much wider use in veterinary medicine. To respond to the wishes of the maker community, next year, we will be releasing a non-degradable version of the patch. This innovation will greatly expand its potential impact!
Collaborations and Future Aspirations
To test and develop its technologies more, Vital3D has been working with Lithuania’s National Cancer Institute. This collaboration will work to create organoids for drug testing in developing cancer drugs and investigate bioprinted stent manufacturing. Šakalys stresses that the company’s work isn’t just about creating hands-on, practical applications right now. They’re setting the stage for the broader advances to come in regenerative medicine.
Vital3D is looking to solve the very problems that exist today with vascularization and cell differentiation. Their intention is to begin with a lower number of cells and increase their arms during production. Vital3D is at the forefront of revolutionizing medical innovation. The company intends to bioprint transplantable, functional human organs for patients with organ failure within the next 10 years.
